Abnova (Taiwan) (TPE:4133) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4133 Abnova (Taiwan) Corp TPE:4133
75 GF Score
Price NT$21.05
GF Value NT$27.92
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Abnova (Taiwan) Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Abnova (Taiwan) is: Moderate Risk: Sensitive, better choose undervalued stock.

Abnova (Taiwan)  (TPE:4133) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Abnova (Taiwan) Risk Assessment Related Terms

TPE:4133 vs VRTX, REGN, RVMD: Risk Assessment Comparison

For the Biotechnology subindustry, Abnova (Taiwan)'s Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abnova (Taiwan) Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s Risk Assessment distribution charts can be found below:

* The bar in red indicates where Abnova (Taiwan)'s Risk Assessment falls into.


TPE:4133
75GF Score
Abnova (Taiwan) Corp TPE:4133
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?

Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued. The current stock price of NT$21.05 is trading 24.6% below its estimated GF Value™ of NT$27.92. GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.

Key valuation signals for TPE:4133:

  • Risk Assessment:
  • GF Value™: NT$27.92 vs. price of NT$21.05 (24.6% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abnova (Taiwan) Business Description

Address No.108, Jhouzih Street, 9th Floor, Neihu District, Taipei City, TWN
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score

Get the complete analysis for TPE:4133

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.05
Price
NT$27.92
GF Value